Brian Rini, MD, on Key Practice Changing Abstracts in Prostate Cancer From 2021 ESMO

Video

Brian Rini, MD, discussed abstracts presented during the 2021 ESMO Congress that will have an immediate impact on prostate cancer.

CancerNetwork® spoke with Brian Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, about intriguing abstracts presented at the 2021 European Society for Medical Oncology (ESMO) Congress. He mentioned a pair of abstracts in prostate cancer that will impact practice moving forward.

Transcription:

In prostate cancer, there were 2 studies presented that will change practice. One was called PEACE-1 (NCT01957436), which looked at triplet therapy versus doublet therapy in prostate cancer. [The trial compared] 2 different hormonal agents plus chemotherapy versus just 1 hormone agent plus chemotherapy and showed a survival advantage that will absolutely impact practice. And then another in the rising PSA setting, looking at double hormone therapy versus single hormone therapy that also showed great results. I think those will immediately change practice.

Reference

Fizazi K, Charles Galceran J, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novel metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. J Clin Oncol. 2021;39(no. 15_suppl):5000-5000. doi: 10.1200/JCO.2021.39.15_suppl.5000

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content